Every material Form 8-K Medpace filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Medpace reported third-quarter 2025 revenue of $659.9 million, up 23.7% from a year earlier, and GAAP diluted earnings per share of $3.86, up from $3.01. Net income margin slipped to 16.8% from 18.1%, and the filing gives 2025 revenue and EPS forecasts but no prior forecast to compare them with.
Q3 2025 revenue $659.9 million, up 23.7% from $533.3 million; EBITDA $148.4 million, up 24.9%
Q3 net new business awards $789.6 million, up 47.9%, for a book-to-bill ratio of 1.20x
Q3 GAAP net income $111.1 million, or $3.86 per diluted share, vs $96.4 million, or $3.01, a year earlier
2025 guidance: revenue $2.480 billion to $2.530 billion and GAAP diluted EPS $14.60 to $14.86
Medpace reported second-quarter 2025 revenue of $603.3 million, up 14.2% from a year earlier, and GAAP diluted earnings of $3.10 per share, up from $2.75. Net income margin fell to 15.0% from 16.7%, and backlog declined 1.8% to $2,873.6 million, while the company repurchased $518.5 million of its stock in the quarter and issued full-year 2025 guidance.
Q2 2025 revenue $603.3 million, up 14.2% from $528.1 million; GAAP net income $90.3 million, or $3.10 per diluted share, vs. $2.75 a year earlier
Full-year 2025 guidance: revenue $2.420 billion to $2.520 billion; GAAP net income $405.0 million to $428.0 million; diluted EPS $13.76 to $14.53
Q2 share repurchases of 1,754,264 shares for $518.5 million; $826.3 million remained under the program as of June 30, 2025
Amendment No. 9 to the PNC Bank unsecured credit facility, dated July 17, 2025, sets line-of-credit borrowing of up to $10 million
At its May 16, 2025 annual meeting, Medpace stockholders approved the Amended 2016 Incentive Award Plan, which extends the plan's expiration date to February 6, 2035 without adding authorized shares. Stockholders also elected August J. Troendle and Dani S. Zander as Class III directors, ratified Deloitte & Touche LLP as auditor for 2025, and approved an advisory say-on-pay vote and a non-binding simple majority voting proposal.
Amended 2016 Plan extends expiration to February 6, 2035 and does not increase authorized shares; approved 25,567,981 for, 702,406 against
Troendle received 21,156,998 votes for and 5,128,383 withheld; Zander received 25,858,694 for and 426,687 withheld
Advisory say-on-pay approved with 24,918,234 for and 1,340,033 against
Non-binding simple majority voting proposal approved with 18,210,462 for and 8,021,457 against
Medpace reported first-quarter 2025 revenue of $558.6 million and GAAP diluted EPS of $3.67, both up from the prior-year quarter, and issued 2025 guidance of $2.140 billion to $2.240 billion in revenue and $12.26 to $13.04 in diluted EPS. Its board also raised the stock repurchase program by $1.0 billion on April 17, 2025, and the company amended its $600 million unsecured credit facility with PNC Bank.
Q1 2025 revenue was $558.6 million, up 9.3% from $511.0 million; GAAP net income was $114.6 million, or $3.67 per diluted share, versus $3.20 a year earlier.
Net new business awards fell 18.8% to $500.0 million, giving a 0.90x book-to-bill ratio; backlog decreased 2.1% to $2,846.0 million.
Board approved a $1.0 billion increase to the stock repurchase program on April 17, 2025; $344.8 million remained under the program at March 31, 2025.
Full-year 2025 guidance: revenue of $2.140 billion to $2.240 billion and GAAP diluted EPS of $12.26 to $13.04.
Medpace Holdings and subsidiaries signed Amendment No. 7 to its unsecured credit facility with PNC Bank, National Association, on March 28, 2025. The amendment extends the expiration date of the revolving credit note to March 31, 2026, keeping the company's existing borrowing arrangement in place for another year.
Agreement dated March 28, 2025 with PNC Bank, National Association, under the unsecured credit facility
Amendment No. 7 extends the revolving credit note expiration date to March 31, 2026
Medpace, Inc. is borrower and Medpace IntermediateCo, Inc. is guarantor; full text filed as Exhibit 10.1
Medpace reported fourth-quarter 2024 revenue of $536.6 million, up 7.7%, and GAAP diluted earnings of $3.67 per share, up from $2.46 a year earlier. The board also approved a $600 million increase to the stock repurchase program, and the company forecast 2025 revenue of $2.110 billion to $2.210 billion, growth of 0.0% to 4.8%, for shareholders to weigh against slower new business awards.
Q4 2024 revenue was $536.6 million, up 7.7% from $498.4 million; GAAP net income was $117.0 million.
Q4 2024 net new business awards fell 13.8% to $529.7 million, for a net book-to-bill ratio of 0.99x.
2025 guidance: revenue of $2.110 billion to $2.210 billion and GAAP diluted EPS of $11.93 to $12.69.
On February 6, 2025, the board approved a $600 million increase to the stock repurchase program.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Medpace filing is on SEC EDGAR ↗. 8-K briefs of other companies →